CONFERENCE COVERAGE SERIES
2019 DIAD Family Conference: Mutation, Participation, Innovation.
Los Angeles, California
13 July 2019
On July 13, the day before the Alzheimer’s Association International Conference started in Los Angeles, 263 DIAN participants and their partners met in the same location with scientists, clinicians, research funders, and representatives of the association for a pre-meeting. They celebrated a shared commitment to use the scientific opportunities inherent in dominantly inherited Alzheimer’s disease toward a better understanding and clinical trials to prevent the disease. Four stories in this series showcase the resilience of DIAN participants, progress in AD genetics, a first look at emerging RNA-based therapies, and an update on DIAN clinical trials.
DIAD: Families from Argentina, Canada, Minnesota Rally a Global Community
A brother’s survival guilt, a journalist tracing her mutation to Lebanon, a student freezing her eggs ahead of a primary prevention trial—DIAN family members are stirring their growing community to act against Alzheimer’s disease.
Genetics Propels DIAN Toward Therapies
Nearly 30 years after the first Alzheimer’s gene discoveries, genetics once again drives recruitment, scientific progress, and therapy development in the Dominantly Inherited Alzheimer’s Network.
ASOs: Wave of the Future in Alzheimer’s Therapeutics?
As the Alzheimer’s field suffers smackdowns in trials of small molecules and antibodies, antisense oligonucleotides are quietly coming along—and looking safe so far.
As DIAN Wraps Up Anti-Aβ Drug Arms, it Sprouts Tau, Primary Prevention Arms
The DIAN Trials Unit is nearing the end of its first two secondary prevention trials. It has begun a cognitive run-in period for its next trial, of a tau-based drug, and for a primary prevention study in people as young as 18.